1. Home
  2. STELLA PHARMA NEWS
STELLA PHARMA NEWS
April 15th, 2025

Phase I/II Clinical Trial in Japan for Thoracic Malignant Solid Tumors has started

 Stella Pharma announces that it has started the first patient trial for the do……

READ MORE

April 9th, 2025

Presentation on the Clinical Trial for Recurrent High-Grade Meningioma at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO)

At the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO),……

READ MORE

March 25th, 2025

Osaka/Kansai EXPO 2025 – We Are Participating

We are proud to announce that we will exhibit at the Osaka Healthcare Pavilion ……

READ MORE

December 25th, 2024

Stella Pharma Concludes MOU on Boron Neutron Capture Therapy System with Fujita Health University, Atransen Pharma, SHI, and Fujita

Stella Pharma Corporation has concluded a Memorandum of Understanding (MOU) to ……

READ MORE

December 10th, 2024

Observation Period Completed for Primary Endpoint – Phase II Clinical Trial in Patients with Angiosarcoma

We are pleased to announce the completion of the 90-day observation period for ……

READ MORE

December 6th, 2024

Paper published: Poly(vinyl alcohol) Potentiating an Inert D-Amino Acid-Based Drug for Boron Neutron Capture Therapy

The paper titled “Poly(vinyl alcohol) potentiating an inert D-amino acid-based ……

READ MORE

November 20th, 2024

Paper published: Research on Combination of Proton Beam Therapy and Boron Nuclear Capture Reaction

The Paper titled “Increased cell killing effect in neutron capture enhanced pro……

READ MORE

November 14th, 2024

Announcement of Agreement Conclusion with TAE LIFE SCIENCES for Collaboration in the Development and Commercialization of BPA Drug for BNCT in Europe and the US

STELLA PHARMA CORPORATION announced today that our Company has entered into a D……

READ MORE

September 25th, 2024

Orphan Drug Designation for Borofalan (10B) (SPM-011) as treatment of Recurrent Malignant Glioma and Recurrent Meningioma

Our product Borofalan (10B) (development code: SPM-011), which we are developin……

READ MORE

September 10th, 2024

Patient Enrollment Completed for Phase II Clinical Trial in Japan on Angiosarcoma

Stella Pharma completed the enrollment of patients for the domestic phase II do……

READ MORE

September 6th, 2024

Conclusion of an Agreement with the National Cancer Center, Sumitomo Heavy Industries, Ltd. and CICS, Inc. for Clinical Trial of BNCT

Stella Pharma announces that it has signed an agreement with the National Cance……

READ MORE